Resources from the same session
Trastuzumab emtansine (T-DM1) vs trastuzumab (H) in Chinese patients (pts) with residual invasive disease after neoadjuvant chemotherapy for HER2-positive breast cancer (BC) in the phase III KATHERINE study
Presenter: Chiunsheng Huang
Session: Proffered paper session - Breast cancer
Resources:
Slides
Webcast
Subgroup analysis of IMpassion130: Atezolizumab + nab-paclitaxel (nab-P) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries
Presenter: Hiroji Iwata
Session: Proffered paper session - Breast cancer
Resources:
Slides
Webcast
Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): Data from phase III EMBRACA
Presenter: Kyung-Hun Lee
Session: Proffered paper session - Breast cancer
Resources:
Slides
LBA6 - First China-manufactured trastuzumab biosimilar HLX02 global phase III trial met primary endpoint in breast cancer
Presenter: Binghe Xu
Session: Proffered paper session - Breast cancer
Resources:
Abstract
Invited Discussant 25O and LBA6
Presenter: Sung-Bae Kim
Session: Proffered paper session - Breast cancer
Resources:
Slides
Invited Discussant 37O and 38O
Presenter: Yoon Sim Yap
Session: Proffered paper session - Breast cancer
Resources:
Slides
Webcast